REGULATION OF BONE FORMATION IN RENAL OSTEODYSTROPHY

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 肾性骨营养不良是一系列骨骼疾病，范围从继发性甲状旁腺功能亢进（2 HPT）的高转换病变（其中血清甲状旁腺激素（PTH）水平显著升高）到低转换病变（如粘连性骨）（其中血清PTH水平正常或轻微升高）。 在终末期肾病（ESRD）儿童中，2 HPT仍然是最常见的疾病，通常需要使用骨化三醇治疗。每周两次大剂量的骨化三醇通常用于降低2 HPT患者的血清PHT水平并降低骨形成和转换，但仅在治疗8至12个月后即可发展为肾上腺性肾性骨营养不良。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Renal osteodystrophy is a spectrum of skeletal disorders ranging from high-turnover lesions of secondary hyperparathyroidism (2HPT), in which serum parathyroid homornes (PTH) levels are substantially elevated, to low-turnover lesions such as adynamic bone, in which serum PTH levels are normal or minimally increased. In children with end-stage renal disease (ESRD), 2HPT remains the most common disorder, and treatment with calcitriol is often required. Large twice-weekly doses of calcitriol are commonly used to reduce serum PHT levels and lower bone formation and turnover in those patients with 2HPT, but adynamic renal osteodystrophy can develop after only eight to 12 months of treatment.